Trial reportOphthalmic epidemiology2013
Emerging moxifloxacin resistance in Pseudomonas aeruginosa keratitis isolates in South India.
Trial report in Ophthalmic epidemiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 57 citations in OpenAlex.
- Systematic Review of Antimicrobial Therapies and Clinical Outcomes inLife (Basel, Switzerland) · 2026Review
- Genotypic Resistance Analysis of Bacterial Species Involved in Infectious Keratitis.Diagnostics (Basel, Switzerland) · 2026Article
- Cefiderocol and Moxifloxacin Have Additive and Synergistic Activity Against Pseudomonas aeruginosa Including an Isolate of the 2023 Keratitis Outbreak.Investigative ophthalmology & visual science · 2025Article
- Clinical characteristics and antibiotic susceptibility patterns of bacterial keratitis in the South of Vietnam.International ophthalmology · 2025Article
- Resistance trend in bacteria isolated from corneal ulcers: A retrospective analysis from Pakistan.PloS one · 2025Article
- Characteristics of Pseudomonas aeruginosa keratitis at Ho Chi Minh eye hospital.International ophthalmology · 2024Article
- The antibiotic resistance profiles of Pseudomonas aeruginosa in the Asia Cornea Society Infectious Keratitis Study.International ophthalmology · 2024Article
- The Role ofPharmaceutics · 2024Review
- Antimicrobial resistance in topical treatments for microbial keratitis: protocol for a systematic review and meta-analysis.BMJ open · 2023Article
- Review
- Potential new fluoroquinolone treatments for suspected bacterial keratitis.BMJ open ophthalmology · 2022Review
- Antimicrobial Activity of a Triple Antibiotic Combination Toward Ocular Pseudomonas aeruginosa Clinical Isolates.Translational vision science & technology · 2022Article
- 12-year analysis of incidence, microbiological profiles and in vitro antimicrobial susceptibility of infectious keratitis: the Nottingham Infectious Keratitis Study.The British journal of ophthalmology · 2021Article
- Multifunctional Monoclonal Antibody TargetingVaccines · 2020Article
- Prevalence and Antibiotic Susceptibility of Bacterial Isolates From Dogs With Ulcerative Keratitis in Midwestern United States.Frontiers in veterinary science · 2020Article
- A Novel, Broad-Spectrum Antimicrobial Combination for the Treatment of Pseudomonas aeruginosa Corneal Infections.Antimicrobial agents and chemotherapy · 2019Article
- The Utility of Colistin in Multiple Drug-ResistantTurkish journal of ophthalmology · 2019Article
- Glycyrrhizin Use for Multi-Drug Resistant Pseudomonas aeruginosa: In Vitro and In Vivo Studies.Investigative ophthalmology & visual science · 2019Article
- Microbiological Profile of Corneal Ulcers at a Tertiary Referral Center.Medical hypothesis, discovery & innovation ophthalmology journal · 2019Article
- Development of a Broad-Spectrum Antimicrobial Combination for the Treatment of Staphylococcus aureus and Pseudomonas aeruginosa Corneal Infections.Antimicrobial agents and chemotherapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeTo describe temporal trends in Pseudomonas aeruginosa resistance to moxifloxacin in keratitis isolates from South India.
methodsThe Steroids for Corneal Ulcers Trial (SCUT) was a randomized, double-masked, placebo-controlled trial assessing outcomes in patients with culture positive bacterial corneal ulcers randomized to receive prednisolone phosphate or placebo. All patients received moxifloxacin, and susceptibility to moxifloxacin was measured at baseline using Etest. We investigated trends in moxifloxacin susceptibility of P. aeruginosa during 2007, 2008, and 2009 isolated in SCUT in South India.
resultsThere were 89 P. aeruginosa isolates during 2007, 2008, and 2009 in SCUT that were eligible for this study. There was an increase in the proportion of resistant isolates from 19% in 2007 to 52% in 2009 (p = 0.02, χ(2) test for trend). Logistic regression showed that there was a 2-fold increase in odds of resistance per 1 year increase during the study period (odds ratio 2.16, 95% confidence interval 1.09-4.26, p = 0.027).
conclusionsWe found a sharp increase in the proportion of isolates that were resistant to moxifloxacin from 2007 to 2009. Further work needs to be done to characterize the nature of this increase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.